

**ASX/Media Release**  
**28<sup>th</sup> November 2014**

## **Board Appointment**

**Sydney, 28<sup>th</sup> November, 2014: OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company)** is pleased to announce the appointment of Mr Daniel Kenny as a Director of the Company.

As announced on 11<sup>th</sup> November, Mr Kenny will commence as CEO on 5<sup>th</sup> January 2015.

OncoSil also advises that Dr Neil Frazer resigned as a director effective today. Executive Chairman, Dr Roger Aston, expressed his appreciation for the contribution made by Dr Frazer during his time on the Board.

ENDS

Contact:  
Dr Roger Aston  
Chairman  
E [rogeraston@aol.com](mailto:rogeraston@aol.com)  
T + 612 402 762 204

### **About OncoSil Medical Ltd**

OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian biotechnology company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical's lead product is OncoSil™ with the first target indication being pancreatic cancer. OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumours outside of pancreatic cancer. FDA and EMA approval for pancreatic cancer is the core focus of OncoSil Medical.

### **Pancreatic Cancer**

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2010 280,000 people globally were diagnosed with pancreatic cancer including 43,140 Americans, 70,000 Europeans and 2,546 in Australia. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The world-wide market for pancreatic drugs is projected by Global Industry Analysis to exceed US\$1.2bn by 2015.